UPDATE: FDA Lifts Clinical Hold on PharmAthene's SparVax Program

PharmAthene, Inc. (NYSE: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on a proposed Phase II study of SparVax^®, a next generation recombinant anthrax vaccine. In a letter to the Company,